| Name | Title | Contact Details |
|---|
So—MAT—us is derived from the Latin word `Somata`, the plural form of `Soma`, which are the cells of the body—free of germ cells. We take Somatus to mean “our healthy bodies”.
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.
Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.
Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.